Search Result
Results for "
Gly6
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N0120A
-
Polydatin
Maximum Cited Publications
14 Publications Verification
Piceid
|
Autophagy
Apoptosis
Mitophagy
|
Inflammation/Immunology
Cancer
|
|
Polydatin (Piceid), extracted from the roots of Reynoutria japonica, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models. Polydatin (Piceid) inhibits G6PD and induces oxidative and ER stresses.
|
-
-
- HY-W107464
-
|
|
PDI
|
Metabolic Disease
Inflammation/Immunology
|
|
G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells .
|
-
-
- HY-W010342
-
|
|
NADPH Oxidase
|
Cancer
|
|
6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP +-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .
|
-
-
- HY-16438
-
RRx-001
Maximum Cited Publications
20 Publications Verification
Nibrozetone
|
CD47
Apoptosis
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity .
|
-
-
- HY-123962
-
|
|
NADPH Oxidase
|
Metabolic Disease
|
|
G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) agonist with an EC50 of 3 μM. G6PD is an oxidoreductase that catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone and the simultaneous reduction of NAD phosphate (NADP) to reduced NADP (NADPH). G6PD activator AG1 can reduce hemolysis of human erythrocytes .
|
-
-
- HY-125863
-
|
G6PD
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .
|
-
-
- HY-18705
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
Caspase
Bcl-2 Family
Mitochondrial Metabolism
|
Endocrinology
|
|
Azoramide is a potent, orally active small-molecule modulator of the unfolded protein response (UPR). Azoramide improves ER protein folding and elevates ER chaperone capacity, which together protects cells against ER stress. Azoramide alleviates PLA2G6 mutant-induced ER stress through modulating unfolded protein response, and enhances the CERB signaling to rescue mitochondrial function, thereby preventing apoptosis of DA neurons. Azoramide has antidiabetic activity .
|
-
-
- HY-P990925
-
|
BLYG8824A; RG6286
|
CD3
|
Inflammation/Immunology
|
|
Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and CD3. Linclatamig can bind to LY6G6D and CD3-positive T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in colorectal cancer research .
|
-
-
- HY-W590989
-
|
GPhos Pd G6 TES
|
Drug Intermediate
|
Others
|
|
GPhos Pd G6 (GPhos Pd G6 TES) is a palladium catalyst. GPhos Pd G6 catalyzes the Buchwald-Hartwig amination reaction and promotes C-N bond formation between aryl chlorides and amines. GPhos Pd G6 is a pharmaceutical intermediate used for the synthesis of various active compounds .
|
-
-
- HY-123046
-
-
-
- HY-W017960
-
|
Et-HE; 1,4-DHP
|
SOD
|
Endocrinology
|
|
Diludine (BNP-7787) is an orally effective feed additive. Diludine reduces the activity of G6PD and increases the level of superoxide dismutase (SOD). Diludine reduces the mutagenic effect of environmental pollutants, protects parental reproductive systems and improves offspring quality. Diludine is mainly applied during the transition period of dairy cows to increase milk yield and milk fat content, and improve health status during parturition. Diludine can be used in animal feeding research .
|
-
-
- HY-115449
-
|
94G6
|
IGF-1R
Akt
mTOR
|
Cancer
|
|
Chromeceptin (94G6) is an IGF signaling pathway inhibitor. Chromeceptin suppresses IGF2 expression at mRNA and protein levels in hepatocyte and HCC cells. Chromeceptin inhibits the phosphorylation levels of AKT and mTOR .
|
-
-
- HY-W587796
-
|
6-PGδL; 6-Phosphonoglucono-D-lactone
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
6-Phosphoglucono-δ-lactone (6-PGδL), a reversal substrate of glucose-6-phosphate dehydrogenase (G6PD), is an intermediate compound in the oxidative branch of the pentose phosphate pathway (PPP). 6-Phosphoglucono-δ-lactone produced from D-glucose-6-phosphate by glucose-6-phosphate dehydrogenase (G6PDH) and is converted to 6-phosphoglutonate by lactonase. 6-Phosphoglucono-δ-lactone can be used for heart failure, type 2 diabetes and cancers research .
|
-
-
- HY-130687A
-
|
DL-Psicose
|
PI3K
mTOR
Akt
IGF-1R
|
Inflammation/Immunology
|
|
Psicose is a natural and low-calorie sweetener. Psicose can activate the PI3K/Akt/mTOR pathway to promote muscle synthesis. Psicose can upregulate IGF-1 and downregulate Myostatin. Psicose regulates mitochondrial function by increasing G6P activity. Psicose enhances antioxidant enzyme activity and reduces oxidative stress markers. Psicose reduces plasma triglycerides and total cholesterol. Psicose can improve muscle fiber size and reduce fibrosis. Psicose can be used for research on sarcopenia .
|
-
-
- HY-P0148
-
|
HexaGlycine
|
Bacterial
|
Others
|
|
Gly6 (Hexaglycine) is a linear glycine oligopeptide with six glycines .
|
-
-
- HY-P10109
-
|
|
Glucose-6-Phosphate Isomerase (GPI)
|
Inflammation/Immunology
|
|
G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .
|
-
-
- HY-125539
-
|
|
Antibiotic
Phosphatase
Fungal
|
Infection
|
|
Roridin E is a glucose-6-phosphatase (G6Pase) inhibitor and antibiotic, and is a metabolic byproduct of Roridin A (HY-N9599). Roridin E induces significant oxidative stress, characterized by depletion of glutathione in vivo, induction of hepatic lipid peroxidation, and inhibition of renal superoxide dismutase activity. Roridin E reduces blood glucose levels in rats, but exhibits acute toxicity (which is enhanced when co-administered with linoleic acid (HY-N0729)) and causes hepatotoxicity in male albino mice. Roridin E induces a decrease in total blood protein and increases in the levels of total lipids, γ-glutamyltransferase, alkaline phosphatase, and 5'-nucleotidase. Roridin E can be isolated from molds, and possesses cytostatic and antifungal activities similar to those of Verrucarin A (HY-107426) and Roridin A. Roridin E exhibits in vivo activity in rodents and is commonly used in hepatotoxicity-related studies .
|
-
-
- HY-106328
-
-
-
- HY-N0120AR
-
|
Piceid (Standard)
|
Reference Standards
Autophagy
Apoptosis
Mitophagy
|
Inflammation/Immunology
Cancer
|
|
Polydatin (Standard) is the analytical standard of Polydatin. This product is intended for research and analytical applications. Polydatin (Piceid), extracted from the roots of Reynoutria japonica, a widely used traditional Chinese remedies, possesses anti-inflammatory activity in several experimental models. Polydatin (Piceid) inhibits G6PD and induces oxidative and ER stresses.
|
-
-
- HY-111896
-
|
7-O-Methoxyrosmanol
|
PEPCK
|
Others
|
|
7-Methoxyrosmanol (7-O-Methoxyrosmanol), a phenolic diterpene isolated from rosemary, suppresses the cAMP responsiveness of PEPCK and G6Pase promoters .
|
-
-
- HY-RS05191
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
G6PC1 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6PC1 Human Pre-designed siRNA Set A
G6PC1 Human Pre-designed siRNA Set A
-
- HY-16443
-
-
-
- HY-122949
-
-
-
- HY-W010342R
-
|
|
NADPH Oxidase
Reference Standards
|
Cancer
|
|
6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .
|
-
-
- HY-W017960R
-
|
Et-HE (Standard); 1,4-DHP (Standard)
|
SOD
Reference Standards
|
Metabolic Disease
|
|
Diludine (Standard) is the analytical standard of Diludine (HY-W017960). This product is intended for research and analytical applications. Diludine (BNP-7787) is an orally effective feed additive. Diludine reduces the activity of G6PD and increases the level of superoxide dismutase (SOD). Diludine reduces the mutagenic effect of environmental pollutants, protects parental reproductive systems and improves offspring quality. Diludine is mainly applied during the transition period of dairy cows to increase milk yield and milk fat content, and improve health status during parturition. Diludine can be used in animal feeding research .
|
-
-
- HY-P10109A
-
|
hG6PI (325-339) hydrochloride
|
Glucose-6-Phosphate Isomerase (GPI)
|
Inflammation/Immunology
|
|
G6PI 325-339 (human) hydrochloride is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) hydrochloride primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) hydrochloride induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .
|
-
-
- HY-RS05194
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
G6PD Human Pre-designed siRNA Set A contains three designed siRNAs for G6PD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6PD Human Pre-designed siRNA Set A
G6PD Human Pre-designed siRNA Set A
-
- HY-RS05192
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
G6PC2 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6PC2 Human Pre-designed siRNA Set A
G6PC2 Human Pre-designed siRNA Set A
-
- HY-RS10633
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
PLA2G6 Human Pre-designed siRNA Set A contains three designed siRNAs for PLA2G6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
PLA2G6 Human Pre-designed siRNA Set A
PLA2G6 Human Pre-designed siRNA Set A
-
- HY-RS05193
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
G6PC3 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6PC3 Human Pre-designed siRNA Set A
G6PC3 Human Pre-designed siRNA Set A
-
- HY-RS07900
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
LY6G6F Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6F gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
LY6G6F Human Pre-designed siRNA Set A
LY6G6F Human Pre-designed siRNA Set A
-
- HY-RS07898
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
LY6G6C Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
LY6G6C Human Pre-designed siRNA Set A
LY6G6C Human Pre-designed siRNA Set A
-
- HY-RS07899
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
LY6G6D Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
LY6G6D Human Pre-designed siRNA Set A
LY6G6D Human Pre-designed siRNA Set A
-
- HY-RS28398
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ly6g6f Rat Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6f gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ly6g6f Rat Pre-designed siRNA Set A
Ly6g6f Rat Pre-designed siRNA Set A
-
- HY-18293
-
|
|
JAK
Autophagy
|
Cancer
|
|
NSC 33994 (G6) is a selective JAK2 inhibitor, with an IC50 of 60 nM .
|
-
-
- HY-117746
-
|
|
Bacterial
|
Infection
|
|
KSK120 is a potent inhibitor of drug-resistant infections with specific activity against Chlamydia trachomatis (C. trachomatis). KSK120 inhibits the developmental cycle of C. trachomatis, thereby reducing the infectivity of progeny bacteria. KSK120 targets the glucose-6-phosphate (G-6P) metabolic pathway of C. trachomatis, showing its potential application in antimicrobial inhibition. The mechanism of KSK120 may involve inhibition of the transcriptional machinery, which provides new ideas for the development of specific drugs against C. trachomatis infection .
|
-
-
- HY-138877A
-
|
|
Phosphatase
|
Cancer
|
|
Phosphoglycolic acid (lithium) is a competitive inhibitor of phosphoglycerate mutase (PGAM)-B, an enzyme of the glycolytic pathway. Phosphoglycolic acid increases basal and fMLF-induced levels of G6P in intact neutrophils. Phosphoglycolic acid thereby increases upstream intermediates in neutrophils, thereby amplifying the respiratory oxidative burst .
|
-
-
- HY-106328R
-
-
-
- HY-136783
-
|
|
Parasite
|
Infection
|
|
G6PD-IN-2 is a Plasmodium falciparum glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 value of 0.2 μM. G6PD-IN-2 exerts weak inhibitory activity on Plasmodium falciparum glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (PfGluPho) with an IC50 value of 22.0 μM. G6PD-IN-2 inhibits growth of Plasmodium falciparum 3D7 strain and exhibits low cytotoxicity in hepatocytes. G6PD-IN-2 can be used for the research of malaria .
|
-
-
- HY-186004
-
-
-
- HY-P992086
-
|
|
VEGFR
|
Cancer
|
|
Anti-Mouse VEGF Antibody (G6-31) is a anti-mouse VEGF antibody. Anti-Mouse VEGF Antibody (G6-31) blocks VEGF-A-mediated angiogenesis and shows antitumor activity. Anti-Mouse VEGF Antibody (G6-31) can be used for the research of cancer, such as multiple endocrine neoplasia type 1 .
|
-
-
- HY-W834690
-
|
|
Phosphatase
|
Metabolic Disease
|
|
G6Pase catalytic enzyme-IN-1 is a competitive inhibitor of glucose-6-phosphatase catalytic enzyme. G6Pase catalytic enzyme-IN-1 has an IC50 of 10 μM in pig liver microsomes. G6Pase catalytic enzyme-IN-1 can be used in studies related to type 2 diabetes .
|
-
-
- HY-RS22997
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
G6pd Rat Pre-designed siRNA Set A contains three designed siRNAs for G6pd gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6pd Rat Pre-designed siRNA Set A
G6pd Rat Pre-designed siRNA Set A
-
- HY-RS05195
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
G6PR Human Pre-designed siRNA Set A contains three designed siRNAs for G6PR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6PR Human Pre-designed siRNA Set A
G6PR Human Pre-designed siRNA Set A
-
- HY-RS27449
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
G6pc3 Rat Pre-designed siRNA Set A contains three designed siRNAs for G6pc3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6pc3 Rat Pre-designed siRNA Set A
G6pc3 Rat Pre-designed siRNA Set A
-
- HY-RS20932
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
G6pc3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for G6pc3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6pc3 Mouse Pre-designed siRNA Set A
G6pc3 Mouse Pre-designed siRNA Set A
-
- HY-RS21881
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ly6g6f Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6f gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ly6g6f Mouse Pre-designed siRNA Set A
Ly6g6f Mouse Pre-designed siRNA Set A
-
- HY-RS26283
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ly6g6d Rat Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6d gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ly6g6d Rat Pre-designed siRNA Set A
Ly6g6d Rat Pre-designed siRNA Set A
-
- HY-RS19787
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Ly6g6d Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6d gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Ly6g6d Mouse Pre-designed siRNA Set A
Ly6g6d Mouse Pre-designed siRNA Set A
-
- HY-Y0370
-
|
|
Proteasome
|
Cardiovascular Disease
|
|
6-Chlorooxindole (compound 2) is a selective chymase inhibitor with an IC50 of 470 μM. 6-Chlorooxindole shows >100-fold selectivity for chymase over cathepsin G. 6-Chlorooxindole can be used for the study of cardiovascular disease .
|
-
- HY-P990995A
-
|
7G6 Antibody; 7G6-IgG2a
|
Tau Protein
|
Neurological Disease
|
|
Etalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonal antibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0148
-
|
HexaGlycine
|
Bacterial
|
Others
|
|
Gly6 (Hexaglycine) is a linear glycine oligopeptide with six glycines .
|
-
- HY-P10109
-
|
|
Glucose-6-Phosphate Isomerase (GPI)
|
Inflammation/Immunology
|
|
G6PI 325-339 (human) is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .
|
-
- HY-P0148A
-
|
HexaGlycine hydrochloride
|
Peptides
|
Others
|
|
Gly6 hydrochloride (Hexaglycine hydrochloride) is a linear glycine oligopeptide with six glycines .
|
-
- HY-P10109A
-
|
hG6PI (325-339) hydrochloride
|
Glucose-6-Phosphate Isomerase (GPI)
|
Inflammation/Immunology
|
|
G6PI 325-339 (human) hydrochloride is an efficient inducer of arthritis in B10.Q mice. G6PI 325-339 (human) hydrochloride primes Th1 and Th17 cells cross-reacted with the murine G6PI protein. G6PI 325-339 (human) hydrochloride induces arthritis model operating through a T and B cell-dependent pathway but without antibody effector mechanisms .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P990925
-
|
BLYG8824A; RG6286
|
CD3
|
Inflammation/Immunology
|
|
Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and CD3. Linclatamig can bind to LY6G6D and CD3-positive T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in colorectal cancer research .
|
-
(5)
-
- HY-P99142
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) is an anti-mouse Ly-6G/Ly-6C IgG2b monoclonal antibody. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can deplete neutrophils and monocytes. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can be used for research on immunology .
|
-
(5)
-
- HY-P991184
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody that targets LY6G6D. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P990199
-
|
|
Inhibitory Antibodies
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) is an anti-mouse Ly6G/Ly6C IgG2b monoclonal antibody. Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) can deplete granulocytes and monocytes. Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) can be used for researches on infection conditions and cancer such as pancreatic cancer and Orientia tsutsugamushi infection .
|
-
(5)
-
- HY-P992086
-
|
|
VEGFR
|
Cancer
|
|
Anti-Mouse VEGF Antibody (G6-31) is a anti-mouse VEGF antibody. Anti-Mouse VEGF Antibody (G6-31) blocks VEGF-A-mediated angiogenesis and shows antitumor activity. Anti-Mouse VEGF Antibody (G6-31) can be used for the research of cancer, such as multiple endocrine neoplasia type 1 .
|
-
(5)
-
- HY-P990995A
-
|
7G6 Antibody; 7G6-IgG2a
|
Tau Protein
|
Neurological Disease
|
|
Etalanetug (Mouse IgG2a) (7G6 Antibody) is a mouse monoclonal antibody targeting the HVPGG motif in the microtubule-binding domain of tau protein. Etalanetug (Mouse IgG2a) reduces the levels of insoluble tau protein in multiple brain regions and inhibits the seeding and spread of pathological tau protein. Etalanetug (Mouse IgG2a) is applicable to research related to Alzheimer's disease .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N0120A
-
-
-
- HY-125863
-
|
G6PD
|
Structural Classification
Natural Products
Classification of Application Fields
Metabolic Disease
Endogenous metabolite
Disease Research Fields
Source Classification
Cancer
|
Endogenous Metabolite
|
|
Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .
|
-
-
- HY-125539
-
|
|
Structural Classification
Natural Products
Microorganisms
Source Classification
|
Antibiotic
Phosphatase
Fungal
|
|
Roridin E is a glucose-6-phosphatase (G6Pase) inhibitor and antibiotic, and is a metabolic byproduct of Roridin A (HY-N9599). Roridin E induces significant oxidative stress, characterized by depletion of glutathione in vivo, induction of hepatic lipid peroxidation, and inhibition of renal superoxide dismutase activity. Roridin E reduces blood glucose levels in rats, but exhibits acute toxicity (which is enhanced when co-administered with linoleic acid (HY-N0729)) and causes hepatotoxicity in male albino mice. Roridin E induces a decrease in total blood protein and increases in the levels of total lipids, γ-glutamyltransferase, alkaline phosphatase, and 5'-nucleotidase. Roridin E can be isolated from molds, and possesses cytostatic and antifungal activities similar to those of Verrucarin A (HY-107426) and Roridin A. Roridin E exhibits in vivo activity in rodents and is commonly used in hepatotoxicity-related studies .
|
-
-
- HY-N0120AR
-
-
-
- HY-111896
-
-
-
- HY-122949
-
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-RS05191
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
G6PC1 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS05194
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
G6PD Human Pre-designed siRNA Set A contains three designed siRNAs for G6PD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS05192
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
G6PC2 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS10633
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
PLA2G6 Human Pre-designed siRNA Set A contains three designed siRNAs for PLA2G6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS05193
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
G6PC3 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS07900
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
LY6G6F Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6F gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS07898
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
LY6G6C Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS07899
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
LY6G6D Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS28398
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Ly6g6f Rat Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6f gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS22997
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
G6pd Rat Pre-designed siRNA Set A contains three designed siRNAs for G6pd gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS05195
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
G6PR Human Pre-designed siRNA Set A contains three designed siRNAs for G6PR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS27449
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
G6pc3 Rat Pre-designed siRNA Set A contains three designed siRNAs for G6pc3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS20932
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
G6pc3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for G6pc3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS21881
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Ly6g6f Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6f gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS26283
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Ly6g6d Rat Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6d gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS19787
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Ly6g6d Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ly6g6d gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: